Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover study
Diabetes Obesity and Metabolism2021Vol. 23(6), pp. 1389–1396
Citations Over TimeTop 10% of 2021 papers
Charlotte K. Boughton, Sara Hartnell, Hood Thabit, Tina Poettler, David Herzig, Malgorzata E. Wilinska, Nicole Ashcroft, Judy Sibayan, Nathan Cohen, Peter Calhoun, Lia Bally, Julia K. Mader, Mark L. Evans, Lalantha Leelarathna, Roman Hovorka
Abstract
The use of Fiasp in the CamAPS FX closed-loop system may reduce hypoglycaemia without compromising glucose control compared with standard insulin aspart in adults with T1D.
Related Papers
- → Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry(2016)124 cited
- → In Vitro Stability of Insulin Aspart in Simulated Continuous Subcutaneous Insulin Infusion Using a MiniMed® 508 Insulin Pump(2007)23 cited
- Comparison of insulin pump and insulin aspart 30 in the treatment of newly diagnosed type 2 diabetes(2013)
- A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50 and human insulin: a randomized, quadruple crossover study(2012)
- → 820-P: Faster-Acting Insulin Aspart vs. Insulin Aspart for Adults with Type 1 Diabetes Treated with Insulin Pump and Continuous Glucose Monitoring(2024)